Biocon announced a partnership between Biocon Pharma, a wholly-owned subsidiary of Biocon, and Libbs Farmaceutica, a pharma company in Brazil, to launch generic drugs in Brazil.

This partnership, which marks the entry of Biocon’s generic formulations into Latin America, builds upon a successful association with Libbs, which began in 2017 to launch biosimilar Trastuzumab in Brazil.

As part of the out-licensing deal with Libbs, Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its expertise and reach in Brazil to import, distribute and market, subject to approvals from the Brazilian health regulatory agency, ANVISA.

Siddharth Mittal, CEO and MD, Biocon said, “Expanding our association with Libbs Farmaceutica, a trusted partner, to our generic formulations, will help us establish a firm footing in Latin America, starting with Brazil.”

Abhijit Zutshi, Commercial Head, Global Generics, added, “The partnership with Libbs further builds on Biocon’s ability to forward integrate its portfolio of complex and differentiated APIs into finished dosages.”

Alcebíades de Mendon?a Athayde Junior, Libbs Executive President, commented, “We are very happy with this partnership that is going to make a difference in our patients’ lives. We started with Biocon Biologics years ago, and we were very successful: our Trastuzumab became a leader in the private market, a milestone for our company.”